Perrigo Company plc (NYSE:PRGO) Director Katherine C. Doyle Sells 8,954 Shares

Perrigo Company plc (NYSE:PRGO) Director Katherine C. Doyle sold 8,954 shares of the stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $27.30, for a total transaction of $244,444.20. Following the completion of the sale, the director now owns 6,009 shares in the company, valued at $164,045.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Perrigo Trading Up 2.2 %

Shares of Perrigo stock opened at $27.75 on Friday. The firm has a market cap of $3.78 billion, a PE ratio of -396.43 and a beta of 0.49. The company has a quick ratio of 1.24, a current ratio of 1.99 and a debt-to-equity ratio of 0.80. Perrigo Company plc has a fifty-two week low of $24.82 and a fifty-two week high of $34.60. The business’s fifty day moving average is $27.83 and its two-hundred day moving average is $28.74.

Perrigo (NYSE:PRGO) last issued its quarterly earnings results on Friday, August 2nd. The company reported $0.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.07. Perrigo had a positive return on equity of 6.79% and a negative net margin of 2.81%. The firm had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same period last year, the company earned $0.63 EPS. The firm’s quarterly revenue was down 10.7% on a year-over-year basis. Analysts anticipate that Perrigo Company plc will post 2.57 earnings per share for the current year.

Perrigo Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 17th. Shareholders of record on Friday, August 30th will be paid a dividend of $0.276 per share. This represents a $1.10 dividend on an annualized basis and a yield of 3.98%. The ex-dividend date of this dividend is Friday, August 30th. Perrigo’s dividend payout ratio is currently -1,571.43%.

Analysts Set New Price Targets

PRGO has been the subject of a number of analyst reports. Piper Sandler cut their price target on Perrigo from $36.00 to $35.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. StockNews.com upgraded shares of Perrigo from a “hold” rating to a “buy” rating in a report on Monday, August 5th.

Hedge Funds Weigh In On Perrigo

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Norges Bank purchased a new stake in shares of Perrigo during the fourth quarter valued at approximately $41,982,000. Diamond Hill Capital Management Inc. grew its holdings in Perrigo by 83.2% during the 2nd quarter. Diamond Hill Capital Management Inc. now owns 1,940,067 shares of the company’s stock worth $49,821,000 after acquiring an additional 881,191 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Perrigo by 675.5% in the 2nd quarter. AQR Capital Management LLC now owns 970,637 shares of the company’s stock valued at $24,926,000 after purchasing an additional 845,470 shares in the last quarter. National Bank of Canada FI bought a new position in shares of Perrigo during the first quarter worth about $19,040,000. Finally, Public Employees Retirement Association of Colorado grew its stake in Perrigo by 3,796.5% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 582,216 shares of the company’s stock worth $18,736,000 after purchasing an additional 567,274 shares in the last quarter. 95.91% of the stock is owned by institutional investors and hedge funds.

About Perrigo

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.